Contact aspiration is comparable to stent retriever (SR) as frontline thrombectomy for patients with acute ischaemic stroke resulting from large vessel occlusion (LVO), according to the ASTER* trial presented at the recent International Stroke Conference (ISC 2017) held in Texas, Houston, US.
The phosphodiesterase 3 inhibitor cilostazol may prevent secondary stroke in individuals with a recent history of ischaemic stroke. However, there was a higher incidence of myocardial infarction in this group, according to findings of the PICASSO* study presented at the International Stroke Conference 2017 (ISC 2017) in Houston, Texas, US.
Initiating statin therapy within 24 hours of hospitalization for an acute ischaemic stroke did not appear to affect patient disability at 90 days poststroke, according to findings of the ASSORT* trial presented at the International Stroke Conference 2017 (ISC 2017) in Houston, Texas, US.
Intensive (triple) antiplatelet therapy does not affect the recurrence of ischaemic stroke or transient ischaemic attack (TIA) compared with guideline standard-of-care antiplatelet therapy, but increases the risk of bleeding, according to interim data from the TARDIS* trial presented at the International Stroke Conference 2017 (ISC 2017) in Houston, Texas.
Resuming oral anticoagulation therapy after a lobar or nonlobar intracerebral haemorrhage (ICH) is associated with a lower risk of mortality and favourable functional outcome, according to results of a meta-analysis presented at the International Stroke Conference 2017 (ISC 2017) in Houston, Texas, US.
Individuals with cerebral venous thrombosis (CVT) have a lower likelihood of developing a pulmonary embolism compared with those with deep vein thrombosis (DVT), according to a study presented at the recent International Stroke Conference 2017 (ISC 2017) in Houston, Texas.
Asia's trusted medical magazine for healthcare professionals.
Get your MIMS Pharmacy - Malaysia digital copy today!
A recent study conducted by The University of Hong Kong (HKU) revealed that long-term use of proton pump inhibitors (PPIs) is associated with a significantly increased risk of gastric cancer even in patients who have had Helicobacter pylori eradicated.
New drug applications approved by US FDA as of 1 - 15 June 2017 which includes New Molecular Entities (NMEs) and new biologics. It does not include Tentative Approvals. Supplemental approvals may have occurred since the original approval date.